Aspiration risks factors, microbiology and empiric antibiotics for patients hospitalized with community-acquired pneumonia

J. Marin Corral (Barcelona, Spain), S. Pascual Guardia (Barcelona, Spain), F. Amati (Milan, Italy), S. Aliberti (Milan, Italy), J. Masclans (Barcelona, Spain), N. Soni (San Antonio, United States of America), A. Rodriguez (Tarragona, Spain), O. Sbila (Barcelona, Spain), F. Sanz (Valencia, Spain), G. Sotgiu (Sassari, Italy), A. Anzueto (San Antonio, United States of America), K. Dimakou (Athens, Greece), M. Medenica (Niksic), R. Petrino (Vercelly, Italy), E. Van De Garde (Nieuwegein, Netherlands), M. Restrepo (San Antonio, United States of America)

Source: Virtual Congress 2020 – Lower respiratory tract infections in clinical practice
Session: Lower respiratory tract infections in clinical practice
Session type: E-poster session
Number: 3104
Disease area: Respiratory infections

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
J. Marin Corral (Barcelona, Spain), S. Pascual Guardia (Barcelona, Spain), F. Amati (Milan, Italy), S. Aliberti (Milan, Italy), J. Masclans (Barcelona, Spain), N. Soni (San Antonio, United States of America), A. Rodriguez (Tarragona, Spain), O. Sbila (Barcelona, Spain), F. Sanz (Valencia, Spain), G. Sotgiu (Sassari, Italy), A. Anzueto (San Antonio, United States of America), K. Dimakou (Athens, Greece), M. Medenica (Niksic), R. Petrino (Vercelly, Italy), E. Van De Garde (Nieuwegein, Netherlands), M. Restrepo (San Antonio, United States of America). Aspiration risks factors, microbiology and empiric antibiotics for patients hospitalized with community-acquired pneumonia. 3104

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia
Source: Eur Respir J 2010; 36: 128-134
Year: 2010



Anti-Pseudomonas antibiotic use for hospitalized patients with community-acquired pneumonia
Source: Virtual Congress 2020 – Lower respiratory tract infections in clinical practice
Year: 2020


Trends in empiric antimicrobial therapy and efficiency of care for community-acquired pneumonia in hospitalized Belarussian patients
Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia
Year: 2007


Influence of adherence to clinical guidelines in empiric antibiotics choice on outcomes of community-acquired pneumonia in hospitalized Belarussian patients
Source: Eur Respir J 2005; 26: Suppl. 49, 637s
Year: 2005

Oral antibiotics prior to hospitalisation for community-acquired pneumonia
Source: Eur Respir J 2008; 31: 478-479
Year: 2008


Diagnosis and treatment of nosocomial pneumonia in ALI/ARDS patients
Source: Eur Respir J 2003; 22: 77S-83S
Year: 2003



Antibiotic management of nosocomial pneumonia in children
Source: Eur Respir J 2006; 28: Suppl. 50, 633s
Year: 2006

Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia
Source: Eur Respir J 2009; 33: 153-159
Year: 2009



The approach to antibiotic treatment in community-acquired pneumonia
Source: Annual Congress 2008 - MP14 - The approach to antibiotic treatment in community-acquired pneumonia
Year: 2008

The comparison of hospitalized healthcare-associated pneumonia with community-acquired pneumonia patients
Source: Annual Congress 2010 - Healthcare-associated pneumonia: ventilator-associated pneumonia and pneumonia in hospitalised patients
Year: 2010


The impact of empiric antibacterial therapy on mortality for patients hospitalized with community-acquired pneumonia (CAP)
Source: Eur Respir J 2006; 28: Suppl. 50, 733s
Year: 2006

Pharmacokinetic optimisation of β-lactams for the treatment of ventilator-associated pneumonia
Source: Eur Respir Rev 2007; 16: 45-49
Year: 2007



Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia
Source: Eur Respir J 2011; 37: 1332-1339
Year: 2011



The etiological agents of community-acquired pneumonia in our hospital
Source: Eur Respir J 2006; 28: Suppl. 50, 735s
Year: 2006

Hospital-acquired pneumonia: microbiological data and potential adequacy of antimicrobial regimens
Source: Eur Respir J 2002; 20: 432-439
Year: 2002



Impact of aspiration pneumonia in community-acquired pneumonia and healthcare-associated pneumonia
Source: Annual Congress 2012 - CT findings: educational posters
Year: 2012

Ertapenem therapy for community-acquired pneumonia in the elderly
Source: Eur Respir J 2005; 26: Suppl. 49, 638s
Year: 2005

Are corticosteroids useful in community-acquired pneumonia?
Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia
Year: 2006


Risk factors of paediatric community-acquired pneumonia
Source: Eur Respir J 2011; 37: 724-725
Year: 2011


Comparison of clinical characteristics between healthcare-associated pneumonia and community-acquired pneumonia in patients admitted into secondary hospitals
Source: Annual Congress 2012 - Epidemiology: risk factors and prognosis in respiratory infections
Year: 2012